Who Owns Cepheid?

Cepheid was founded in 1996 by Kurt Petersen, a professor at the University of California, Berkeley, and Gajus Worthington, a Stanford graduate, in Sunnyvale, California. The company was spun out of research conducted at Lawrence Livermore National Laboratory, where microfluidic chip technology was being developed for biological detection. The founding team recognized that rapid, automated molecular testing could replace the slow, labor-intensive PCR workflows that dominated clinical laboratories in the 1990s.

The company's first major product was the SmartCycler system, released in 2002, a real-time PCR instrument capable of running up to 16 samples simultaneously. SmartCycler was adopted by the U.S. military for biodefense applications, including anthrax detection, and by clinical labs for early infectious disease testing. However, SmartCycler still required trained technicians to prepare samples before loading them onto the instrument.

The breakthrough came with the GeneXpert system, launched in 2004. GeneXpert was the first platform to integrate sample preparation, DNA extraction, amplification, and detection into a single self-contained cartridge. A technician loaded a raw clinical sample, closed the lid, and received a result in approximately 60 minutes. This "sample-to-answer" workflow eliminated the need for dedicated molecular laboratory infrastructure and made PCR testing feasible in settings ranging from large hospitals to remote clinics.

In 2004, Cepheid received its first FDA clearance for a Group B Streptococcus test on GeneXpert. The company expanded its test menu throughout the late 2000s, with a major milestone in 2010 when the World Health Organization endorsed GeneXpert for tuberculosis testing. The Xpert MTB/RIF assay could detect Mycobacterium tuberculosis and rifampin resistance in under two hours, compared to traditional culture methods that took weeks. This test became the cornerstone of TB control programs in over 130 countries.

Cepheid went public on NASDAQ in 2000 under the ticker CPHD. Through the 2000s and early 2010s, the company expanded its infectious disease menu to cover healthcare-associated infections (C. difficile, MRSA), sexual health (chlamydia, gonorrhea), and respiratory infections (influenza, RSV). The company also developed oncology and pharmacogenomic assays.

Danaher announced its acquisition of Cepheid on September 6, 2016, for $51 per share, valuing the company at approximately $4.3 billion including debt. The deal closed in November 2016. At the time, Cepheid had annual revenue of approximately $545 million and an installed base of approximately 11,000 GeneXpert systems. The acquisition gave Danaher a leading position in molecular diagnostics and was part of a broader strategy to build out its Diagnostics segment.

Under Danaher ownership, Cepheid expanded rapidly. The GeneXpert installed base grew from approximately 11,000 systems in 2016 to over 30,000 by 2024. The test menu grew from approximately 20 assays to over 50 FDA-cleared tests. During the COVID-19 pandemic, Cepheid's Xpert Xpress SARS-CoV-2 test, released in March 2020, became one of the most widely used rapid molecular COVID tests globally. Respiratory testing revenue peaked at approximately $1.9 billion in 2022 before declining as pandemic demand subsided.

In Q4 2025, Cepheid received FDA clearance for its Xpert GI Panel, a rapid multiplex PCR test detecting 11 common gastrointestinal pathogens from a single patient sample. In July 2026, Cepheid unveiled the third generation of the GeneXpert system at the ADLM Annual Scientific Meeting. The new system features a fully integrated touchscreen interface, redesigned software, and is designed to support future high-plex panel testing and next-generation sequencing workflows. The first compact four-module configuration is expected to begin shipping to U.S. customers in the coming months.

Also in 2026, Cepheid supported the Ebola outbreak response in the Democratic Republic of Congo and Uganda through donation of Xpert Hemorrhagic Fever panel tests, working with global health partners to expand testing capacity in affected regions.